Medical therapy options for aging men with benign prostatic hyperplasia

Focus on alfuzosin 10 mg once daily

Claus Roehrborn, Raymond C. Rosen

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.

Original languageEnglish (US)
Pages (from-to)511-524
Number of pages14
JournalClinical Interventions in Aging
Volume3
Issue number3
StatePublished - 2008

Fingerprint

Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Quality of Life
Safety
Therapeutics
Phosphodiesterase 5 Inhibitors
Adrenergic Antagonists
Erectile Dysfunction
Health Personnel
Antihypertensive Agents
Comorbidity
Heart Diseases
alfuzosin
Hypertension

Keywords

  • Aging
  • Alfuzosin
  • Benign prostatic hyperplasia
  • Cardiovascular system
  • Lower urinary tract symptoms
  • Sexual function

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Medical therapy options for aging men with benign prostatic hyperplasia : Focus on alfuzosin 10 mg once daily. / Roehrborn, Claus; Rosen, Raymond C.

In: Clinical Interventions in Aging, Vol. 3, No. 3, 2008, p. 511-524.

Research output: Contribution to journalArticle

@article{aae3a83cc89745428cd7add0149d2c0c,
title = "Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfuzosin 10 mg once daily",
abstract = "Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.",
keywords = "Aging, Alfuzosin, Benign prostatic hyperplasia, Cardiovascular system, Lower urinary tract symptoms, Sexual function",
author = "Claus Roehrborn and Rosen, {Raymond C.}",
year = "2008",
language = "English (US)",
volume = "3",
pages = "511--524",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Medical therapy options for aging men with benign prostatic hyperplasia

T2 - Focus on alfuzosin 10 mg once daily

AU - Roehrborn, Claus

AU - Rosen, Raymond C.

PY - 2008

Y1 - 2008

N2 - Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.

AB - Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.

KW - Aging

KW - Alfuzosin

KW - Benign prostatic hyperplasia

KW - Cardiovascular system

KW - Lower urinary tract symptoms

KW - Sexual function

UR - http://www.scopus.com/inward/record.url?scp=54949123800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949123800&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 511

EP - 524

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

IS - 3

ER -